ArQule’s Drug Discovery Platform (NASDAQ:ARQL)

ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that has significant therapeutic potential. The data reflected the results of the application of the ArQule Kinase Inhibitor Platform (AKIP) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and that show potent anti-tumor activity in FGFR-driven cancer models.

ArQule is a biotechnology company which looks after the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP for binding to the kinase.

The information presented today shows the speed and efficiency of ArQule’s proprietary structure based drug discovery platform that will identify chemically novel kinase inhibitors that are not ATP-competitive. Several compounds from this program showed marked pharmacodynamic suppression of FGFR2 and corresponding growth inhibition in human gastric carcinoma cell lines. ArQule’s Chief Scientific Officer, Dr. Thomas Chan mentioned that ArQule now has the opportunity to expand the number of chemotypes available for the development against disease relevant kinases in multiple therapeutic areas as they now believe that approximately half of the human kinome may be amenable to this novel mode of inhibition.